The Board of Directors of SoftOx Solutions AS ("SoftOx" or the "Company") has
today resolved to call for an Extraordinary General Meeting ("EGM") on 20th of
December 2024 with the agenda to distribute 100% of the total outstanding shares
in the Company's subsidiary SoftOx Wound & Skin Care (previously named SoftOx
Disinfection AS) ("SoftOx Wound & Skin Care") as a dividend-in-kind to its
shareholders, in total 1 951 253 942 shares. Following the approval of the
dividend proposal at the EGM, and its execution by distribution of the shares,
SoftOx will no longer hold any shares in SoftOx Wound & Skin Care.  

The notice for the EGM is enclosed. 

The proposal to spin out the SoftOx Wound & Skin Care business is in line with
previous communication made by the Company. The Board of Directors is confident
that the proposed dividend distribution aligns with the interests of the
shareholders of SoftOx. With the EGM's approval of this distribution, SoftOx
will accomplish financial deconsolidation of the SoftOx Wound & Skin Care
segment and allow for improved financing terms for both companies. Allocating
shares to SoftOx's current investors will endow SoftOx Wound & Skin Care with a
broader base of direct owners. 

The shares of SoftOx Disinfection will be distributed on a 1:1 basis such that 1
SoftOx share will be entitled to receive a dividend of 1 SoftOx Wound & Skin
Care Share. The Wound & Skin Care shares will not be publicly listed. Further
information will be available on the SoftOx Wound & Skin Care webpage, in due
time. 

Subject to EGM approval, the proposed dividend in kind will be distributed to
shareholders who own shares in the Company at the closing of 23rd December 2024,
i.e., this will be the last day of trading in the shares including the rights to
dividends. The first day of trading in the Company's shares excluding rights to
dividends will be 27th December 2024 (Ex-date). The payment date of the dividend
is expected on or about the 11th of February 2025. For more information on the
proposal for a dividend in kind, please see the attached call for EGM. 

About SoftOx Wound & Skin Care: 
SoftOx Wound & Skin Care AS is the previous SoftOx Disinfection subsidiary and,
after an internal reorganization, the owner of the SoftOx Wound & Skin Care
activities focusing on deploying SoftOx's technology towards new and more
effective treatment methods for eradicating infections in wounds, which is a
significant societal issue and offers substantial revenue potential once
developed. 

For any questions or interview requests, please contact:   

Ulrik Spork, Chair of SoftOx Solutions AS   

Mail: ir@soft-ox.com   

Phone: Ulrik Spork: +45 3138 8387  

About SoftOx Solutions AS: 
SoftOx Solutions AS (SoftOx) is a medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes the holding
company SoftOx Solutions AS, subsidiaries SoftOx Defense Solutions AS and SoftOx
Wound & Skin Care AS, and a Swedish subsidiary Water Innovation AB (WIAB).
SoftOx is developing highly effective antimicrobial solutions for use in
biofilm, viral, and antimicrobial-resistant infections. The patent-protected
technology is based on extensive research and development in partnership with
leading Nordic research institutes.  

For more information on SoftOx, visit www.soft-ox.com